Wall Street Zen upgraded shares of Humana (NYSE:HUM – Free Report) from a hold rating to a buy rating in a research report released on Monday,Wall Street Zen reports.
Several other analysts have also recently weighed in on HUM. JPMorgan Chase & Co. raised their price objective on shares of Humana from $316.00 to $393.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Weiss Ratings raised shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 14th. Mizuho upped their target price on shares of Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Monness Crespi & Hardt raised Humana to a “buy” rating in a research note on Friday, October 9th. Finally, Truist Financial raised their price target on Humana from $415.00 to $475.00 and gave the company a “hold” rating in a research report on Monday, October 12th. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $465.61.
Get Our Latest Report on Humana
Humana Price Performance
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 11.20% and a net margin of 0.88%. The firm had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter last year, the company posted $3.24 EPS. The company’s revenue for the quarter was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities analysts anticipate that Humana will post 9.03 EPS for the current fiscal year.
Humana Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. Humana’s dividend payout ratio (DPR) is 34.44%.
Institutional Investors Weigh In On Humana
A number of institutional investors have recently made changes to their positions in HUM. Johnson Financial Group Inc. purchased a new position in Humana in the 2nd quarter worth $26,000. Trust Co. of Vermont purchased a new stake in Humana during the second quarter valued at about $28,000. Bogart Wealth LLC grew its stake in shares of Humana by 192.0% during the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after buying an additional 48 shares during the last quarter. MidFirst Bank bought a new position in shares of Humana during the second quarter valued at about $35,000. Finally, Global Assets Advisory LLC bought a new position in shares of Humana during the first quarter valued at about $38,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Humana News Summary
Here are the key news stories impacting Humana this week:
- Positive Sentiment: Humana reported a narrower-than-expected third-quarter loss and revenue above estimates, then raised its 2026 adjusted EPS guidance. The results prompted analysts to increase forecasts and price targets: Barclays raised its target to $587, Guggenheim to $521, and Cantor Fitzgerald to $495. Analysts raise forecasts after Q3 results
- Positive Sentiment: A rebound in Humana’s Medicare Advantage star ratings could potentially unlock up to $4.8 billion, offering a longer-term revenue opportunity. The report also notes brokers face reduced compensation. Humana’s stars rebound could unlock $4.8bn
- Neutral Sentiment: Humana began cash tender offers for eight series of senior notes. The debt-management move could reduce outstanding debt, but the announcement does not specify the offers’ overall financial impact. Humana commences offers to purchase debt securities
About Humana
Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.
The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Humana was founded in 1961 as a nursing home company and later expanded into health insurance.
See Also
- Five stocks we like better than Humana
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
